

Diane R Mould

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6658086/publications.pdf>

Version: 2024-02-01

28
papers

1,655
citations

430874

18
h-index

501196

28
g-index

28
all docs

28
docs citations

28
times ranked

1943
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 635-646.	4.7	432
2	Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2247-2259.	1.9	232
3	Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies. <i>BioDrugs</i> , 2010, 24, 23-39.	4.6	173
4	A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 650-660.	1.9	116
5	Drug Development of Therapeutic Monoclonal Antibodies. <i>BioDrugs</i> , 2016, 30, 275-293.	4.6	68
6	Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. <i>AAPS Journal</i> , 2017, 19, 215-222.	4.4	62
7	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	1.5	61
8	Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 662-669.	1.3	56
9	The Pharmacokinetics of Biologics: A Primer. <i>Digestive Diseases</i> , 2015, 33, 61-69.	1.9	48
10	Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. <i>Journal of Clinical Pharmacology</i> , 2015, 55, S51-9.	2.0	44
11	Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside. <i>AAPS Journal</i> , 2014, 16, 925-937.	4.4	41
12	Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 790-802.	2.0	37
13	Dashboard-Driven Accelerated Infliximab Induction Dosing Increases Infliximab Durability and Reduces Immunogenicity. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1375-1385.	1.9	34
14	Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1513-1523.	3.5	30
15	Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets. <i>Malaria Journal</i> , 2014, 13, 36.	2.3	29
16	Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?. <i>AAPS Journal</i> , 2018, 20, 99.	4.4	29
17	Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure–safety relationships. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 336-347.	2.0	27
18	Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies. <i>AAPS Journal</i> , 2017, 19, 1136-1147.	4.4	26

#	ARTICLE	IF	CITATIONS
19	Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 291-308.	2.5	18
20	Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming. AAPS Journal, 2018, 20, 76.	4.4	17
21	Global population pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib in cancer patients: rationale for lower dosage in Asia. British Journal of Clinical Pharmacology, 2018, 84, 35-51.	2.4	13
22	Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach” an Indian experience. European Journal of Clinical Pharmacology, 2021, 77, 55-62.	1.9	13
23	Population Pharmacokinetic–Pharmacodynamic Modeling of Biological Agents: When Modeling Meets Reality. Journal of Clinical Pharmacology, 2010, 50, 91S-100S.	2.0	12
24	Multi-Criteria Decision Analysis Model for Assessing the Risk from Multi-Ingredient Dietary Supplements (MIDS). Journal of Dietary Supplements, 2021, 18, 293-315.	2.6	11
25	Critical Considerations in Anticancer Drug Development and Dosing Strategies: The Past, Present, and Future. Journal of Clinical Pharmacology, 2017, 57, S116-S128.	2.0	9
26	Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection. Journal of Clinical Pharmacology, 2021, 61, 224-233.	2.0	8
27	Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases. Journal of Clinical Medicine, 2022, 11, 3316.	2.4	6
28	Population Pharmacokinetics and Exposure–Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies. Journal of Clinical Pharmacology, 2021, , .	2.0	3